FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

BIOCON

380.7
+1 (0.26%)
Updated 03:28 07/05 IST

BIOCON Buy or Sell - FrontPage Forums

19 Users have submitted 23 trade ideas of Rs. 3,948,239.42 for BIOCON
Disclaimer
100% Bullish
0% Bearish

BIOCON Buy or Sell - Brokerage Reports

No. of reports in last year
8
No. of analysts
4
Average Consensus Forecast
417.62
Consensus Potential
3.57%
See BIOCON Share Price Targets >>

BIOCON Ratings

Long term BIOCON rating by FrontPage users
4.4/5 (7 Ratings)
Find answers to all your questions on live BIOCON message board: Is BIOCON buy or sell? Should I buy BIOCON shares? Why are BIOCON shares falling? Should I invest in BIOCON stock?

  1. Home
  2. BIOCON Forum

BIOCON Share Price Discussion

A
Reputation: 216 • Yesterday 4:10 AM
Biocon Scrip Case: SEBI Imposes Penalty on 6 Entities, Bans Them from Trading for 2 Years
Market regulator the Securities and Exchange Board of India (SEBI) has barred six entities from the markets for two years for indulging in manipulative trading in the shares of Biocon Ltd in the cash market.
Moneylife NEWS & VIEWS
Like
Reply

Type
Buy
Instrument
BIOCON
Entry Price
₹381
Price@Trade
₹381
Target Price
₹405
Stop Price
₹370
Valid Till
May 17, 2021 3:20 AM
Margin
₹19,050 approx for 50 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
BIOCON MAY21 410 CE
Entry Price
₹5.25
Price@Trade
₹5.3
Target Price
₹15
Stop Price
₹0
Valid Till
May 27, 2021 3:20 AM
Margin
₹12,075 approx for 2300 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 6:24 AM

Update
Trade Entered
Entry Price
₹5.25
Like
Reply
Like
Reply

Type
Buy
Instrument
BIOCON
Entry Price
₹384.5
Price@Trade
₹382.35
Target Price
₹386.5
Stop Price
₹382.5
Valid Till
May 7, 2021 3:20 AM
Margin
₹38,450 approx for 100 Qty
Status
Expired before entry
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 8:51 AM

Update
Expired before entry
Price @ Update
₹381.1
R
Reputation: 0 • May 7 4:38 AM

Type
Buy
Instrument
BIOCON MAY21 FUT
Entry Price
₹384.2
Price@Trade
₹384.2
Target Price
₹480
Stop Price
₹300
Valid Till
May 27, 2021 3:20 AM
Margin
₹482,088.05 approx for 4600 Qty
Status
Active
Like
Reply
swap_vert
Trade
N
Reputation: 13,650 • May 7 4:26 AM
Biocon shares up 0.5% as Nifty gains
A total of 35,213 shares changed hands on the counter till 10:51AM (IST).
The Economic Times
Like
Reply
G
Reputation: 0 • May 7 2:57 AM

Type
Buy
Instrument
BIOCON
Entry Price
₹384.5
Price@Trade
₹381.45
Target Price
₹390
Stop Price
₹381.9
Valid Till
May 7, 2021 3:20 AM
Margin
₹3,845 approx for 10 Qty
Status
Expired before entry
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 8:51 AM

Update
Expired before entry
Price @ Update
₹381.1
Like
Reply
Like
Reply
N
Reputation: 13,650 • May 6 6:01 AM
Biocon shares drop 0.51% as Sensex rises
The stock quoted a 52-week high of Rs 487.7 and a 52-week low of Rs 320.9.
The Economic Times
Like
Reply
N
Reputation: 13,650 • May 6 5:41 AM
Second wave of COVID-19 has hit India 'like a tsunami': Kiran Mazumdar Shaw
“This time around the second wave has hit like a tsunami. And the unfortunate part is it has not spared any part of our country,” Mazumdar said during a virtual panel discussion on global vaccine equity organised by One Share World.
The Economic Times
Like
Reply
B
Reputation: 0 • May 6 5:04 AM

Type
Sell
Instrument
BIOCON MAY21 400 PE
Entry Price
₹27.9
Price@Trade
₹27.9
Target Price
₹5
Stop Price
₹38
Valid Till
May 27, 2021 3:20 AM
Margin
₹203,089.42 approx for 2300 Qty
Status
Active
Like
Reply
swap_vert
Trade
S
Reputation: 96 • May 6 4:04 AM
Like
Reply

Type
Buy
Instrument
BIOCON MAY21 380 PE
Entry Price
₹13.35
Price@Trade
₹13.05
Target Price
₹14
Stop Price
₹12.7
Valid Till
May 6, 2021 3:20 AM
Margin
₹30,705 approx for 2300 Qty
Status
Target Achieved
Exit Price
₹14
Net P&L
+₹1,495 (+4.87%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 6 4:05 AM

Update
Trade Entered
Entry Price
₹13.35
TrackerBot @trackerbot
May 6 4:54 AM

Update
Target Achieved
Exit Price
₹14

#BIOCON OPTION BUY 390 CE ABOVE 11.25 (POSITIONAL)
Like
Reply

BIOCON - chart - 2955669
Biocon🔥
Buy 380
SL 370
Target 390,395,400
Always follow Risk management and psychological stability when taking trade.
Being Disciplined is the only thing that pays off in the securities market in long run.
This is only for education purpose, contact your financial advisor befo...
Read more...
1
Reply

Type
Sell
Instrument
BIOCON MAY21 375 PE
Entry Price
₹10.1
Price@Trade
₹10.15
Target Price
₹1
Stop Price
₹12.5  ₹10
Valid Till
May 27, 2021 3:20 AM
Margin
₹252,591.17 approx for 2300 Qty
Status
Stoploss Hit
Exit Price
10.0
Net P&L
+₹230 (+0.09%)
Like
Reply (3)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 6 3:27 AM

Update
Trade Entered
Entry Price
₹10.1
Durgesh @durgesh-Sytd69cMv
May 7 5:04 AM

Update
Stoploss Trailed
Price @ Update
₹9
Original SL
₹12.5
New SL
10.0
TrackerBot @trackerbot
May 7 6:48 AM

Update
Stoploss Hit
Exit Price
10.0

Type
Buy
Instrument
BIOCON MAY21 FUT
Entry Price
₹382
Price@Trade
₹382
Target Price
₹402
Stop Price
₹362
Valid Till
May 27, 2021 3:20 AM
Margin
₹239,292 approx for 2300 Qty
Status
Exited
Exit Price
₹383.3
Net P&L
+₹2,990 (+1.25%)
Like
Reply (1)
swap_vert
Trade
See all replies
S N Rao @snrao-Sk7G2yr8_
May 5 7:53 AM

Update
Exited
Exit Price
₹383.3
Net P&L
+₹2,990 (+1.25%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • BIOCON - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization36,660
    Enterprise Value36,305
    Price to Earnings149.8
    Price to Book Value5.15
    Return on Capital Employed0.04
    Return on Equity0.04
    Face Value5
    Dividend YieldNA
  • BIOCON - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    30-Apr-21Nirmal BangSell302
    18-Feb-21Nirmal BangSell325
    28-Dec-20SharekhanBuy520
    26-Oct-20Axis DirectBuy474
    23-Oct-20ICICIdirect.comBuy500
    BIOCON Brokerage Price Target
  • BIOCON Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    May 7381.55383.95379.4381.15
    May 6382.95384.4377.4379.7
    May 5375382.6370.15381.3
    May 4381382.15372.5373.2
    May 3380.95381.85375.1378.5
  • BIOCON Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹395.93
    30 Day Moving Average₹399.27
    50 Day Moving Average₹397.71
    100 Day Moving Average₹417.6
    200 Day Moving Average₹419.62
  • BIOCON - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,4252,587.9-0.06
    Operating Profit318591.8-0.46
    Profit Before Tax305536.2-0.43
    Net Income238519.3-0.54
  • BIOCON - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds7,1156,7370.06
    Total Liabilities1,1251,0450.08
    Total Assets8,2407,7830.06
  • BIOCON - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity355185.80.91
    Cash from Investing Activity-553104-6.32
    Cash from Financing Activity-54-238.3-0.77
    Net Cash Flow-25251.5-5.89
  • BIOCON - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.07
    Return on Equity0.040.08
    Return on Capital Employed0.040.08
  • BIOCON - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.08
    3 Year CAGR Growth in Operating Profit-0.22
    3 Year CAGR Growth in EBIDTA-0.21
    3 Year CAGR Growth in Net Income-0.34
    3 Yr CAGR Growth - Diluted EPS-0.78
  • BIOCON - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.25
    5 Year CAGR Growth in Operating Profit-0.18
    5 Year CAGR Growth in EBIDTANA
    5 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.71
  • BIOCON - Recent News

    keyboard_arrow_down
    NewsBot
    May 7 4:26 AM
    Biocon shares up 0.5% as Nifty gains
    The Economic Times
    NewsBot
    May 6 6:01 AM
    Biocon shares drop 0.51% as Sensex rises
    The Economic Times
    NewsBot
    May 6 5:41 AM
    Second wave of COVID-19 has hit India 'like a tsunami': Kiran Mazumdar Shaw
    The Economic Times
    NewsBot
    May 5 7:01 AM
    Biocon shares gain 1.71% as Sensex rises
    The Economic Times
    NewsBot
    May 4 6:46 AM
    Biocon shares down 0.44% as Nifty drops
    The Economic Times
    NewsBot
    May 3 5:36 AM
    Share price of Biocon falls as Nifty weakens
    The Economic Times
    NewsBot
    May 2 3:46 AM
    Biocon Biologics provided 7,000 doses of Itolizumab in April
    The Economic Times
    NewsBot
    Apr 30 7:46 AM
    Biocon shares down 3.16% as Sensex falls
    The Economic Times
    NewsBot
    Apr 29 10:36 AM
    Billion dollar target for biologics biz by FY22 unrealistic, but we would soon return to high growth trajectory: Kiran Mazumdar Shaw
    The Economic Times
    NewsBot
    Apr 29 4:31 AM
    Biocon shares gain 1.32% as Sensex falls
    The Economic Times
  • BIOCON - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • BIOCON - More Information

    keyboard_arrow_down

    Biocon Ltd:
    Biocon Limited is a biopharmaceutical firm in India, engaged in developing, manufacturing and selling pharmaceutical products for oncology, diabetes and autoimmune diseases in the nation as well as abroad. The company has several sectors of operations such as small molecules, branded formulations, research services and more.
    The company is manufacturing insulin lispro, insulin glargine, insulin aspart, recombinant human insulin, monoclonal antibodies, small molecules viz. generic formulations and active pharmaceutical ingredients and more, along with botanical products. Besides that, the company has branded formulation products under brands such as Insugen, BIOMAb, ALZUMAb, EGFR, Basalog and CANMAb. Biocon Limited has certifications such as ISO 9001, ISO 14001:2004, ISO 9001:2000, ISO 15189:2003 and OHSAS 18001:1999. The company has been developing its entire research system based upon small and large molecules, oligonucleotides and antibody-drug conjugates. Clinigene International Ltd and Syngene International Ltd are the two subsidiaries of Biocon Limited. The company has a global intervention in approximately 120 countries.
    About Company Information:
    Biocon Limited was incepted in 1978 and is headquartered in Bangalore, India. Biocon Limited was found when an Indian entrepreneur signed a joint venture with Ireland based firm Biocon Biochemicals Limited in 1978. The company started manufacturing and exporting enzymes to USA and Europe from 1979. Biocon Biochemicals Limited was acquired by Unilever plc and merged with Unilever’s subsidiary Quest International.
    In 1990, the company enhanced its in-house research programme by introducing new technologies. In 1993, the R&D, along with manufacturing facilities of the company, was certified ISO 9001 by RWTUV, Germany. Syngene International Pvt. Ltd was incorporated by the company in 1994 as a Custom Research Company for addressing the exponentially increasing need for outsourced Research & Development in the pharmaceutical sector.
    Developing an efficient manufacturing facility, Biocon Limited started to venture its initiatives for human healthcare in the medicine market and business since 1997. In 1998, Unilever had gone for a deal with ICI for selling its speciality chemicals division, which includes Quest International.
    A totally automated submerged fermentation plant, for the first time in its history of operation, was commissioned by the company in 2000, for manufacturing speciality pharmaceuticals. Clinigene, India’s first Clinical Research Organisation for providing clinical research and development was commissioned by the company in 2000. US FSA approved Biocon Limited as India’s first pharmaceutical company to manufacture the cholesterol-lowering molecule lovastatin.
    In 2005, a commercial agreement was signed by Biocon Limited for supplying insulin API to Asia, Africa and the Middle East. Nation’s largest biotechnology hub, having an integrated set up of manufacturing facilities and research laboratories with a spreading of 90 acres in Karnataka Industrial Areas Development Board—namely, Biocon Park was established by the company in 2006. Country’s largest multi-product Biologics facility was also established at Biocon Park.
    An MoU was signed between Biocon and Neopharma, resulting as a joint venture firm Neobiocon in July 2007. A strategic partnership was established between the company and IATRICa, Inc for developing jointly a range of immunoconjugates regarding the immunotherapy of cancers and infectious diseases in January 2008.
    BASALOG, long-lasting basal insulin for Type 1 & Type 2 Diabetics were introduced by Biocon Limited in 2009. Biocon Cell was launched as the resultant of the partnership between Biocon Limited and ISB for Innovation Management in the same year. AxiCorp GmbH, the German subsidiary of Biocon had been sold by the company in 2011, to its existing promoters and shareholders. ALZUMAb, was launched by Biocon Limited in 2013 for the psoriasis patients in India.
    In 2014, CANMAb – Trastuzumab, a medicine for the treatment of breast cancer was launched by the company in India. A world-class premium devices facility was inaugurated by Biocon at Bangalore in 2015 along with the introduction of Basalog One in India. Mylan and Biocon jointly submitted a proposal for Biosimilar Trastuzumab to USFDA in 2016.
    Biocon Limited declared that along with Mylan it is going to enhance the introduction of adalimumab biosimilar in Europe, as Mylan has an in-licensing arrangement with Fujifilm Kyowa Kirin Biologics.
    How Biocon Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Biocon Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Biocon Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Advik Laboratories Ltd. ADVLAB
    Ahlcon Parenterals (India) Ltd. AHLPAR
    Ajanta Pharma Ltd. AJAPHL
    Aurobindo Pharma Ltd. AUROBP
    Bharat Immunological & Biologicals Corporation Ltd. BHAIMM
    Biofil Chemicals & Pharmaceuticals Ltd. BIOCHE
    Biowin Pharma (India) Ltd. BIOPHA
    Bliss GVS Pharma Ltd. BLIGVS
    Brabourne Enterprises Ltd.[Amalgamated] RPGLIF
    Brawn Biotech Ltd. BRAPHA
    Brooks Laboratories Ltd. BROLAB
    Cadila Healthcare Ltd. CADHEA
    Caplin Point Laboratories Ltd. CAPPOI
    Cipla Ltd. CIPLTD
    Claris Lifesciences Ltd. CORELA
    Colinz Laboratories Ltd. COLILA
    Combat Drugs Ltd. COMDRU
    Concord Drugs Ltd. CONDRU
    Coral Laboratories Ltd. CORLAB
    Desh Rakshak Aushdhalaya Ltd. DESRAK
    DIL Ltd. DILLIM
    Divi's Laboratories Ltd. DIVIL
    Dolphin Laboratories Ltd. DOLLAB
    Dr. Datsons Labs Ltd. AANLIF
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Ganga Pharmaceuticals Ltd. GANPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Ipca Laboratories Ltd. IPCLAB
    Ishita Drugs & Industries Ltd. ISHDRU
    J B Chemicals & Pharmaceuticals Ltd. JBCH
    Jagsonpal Pharmaceuticals Ltd. JAGPHA
    Jenburkt Pharmaceuticals Ltd. JENPHA
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Kabra Drugs Ltd. KABDRU
    Kamron Laboratories Ltd. KAMLAB
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Mangalam Drugs and Organics Ltd. MANDRU
    New Heaven Chemicals and Industries Ltd. TRAMED
    NGL Fine - Chem Ltd. NGLFIN
    Norris Medicines Ltd. NORMED
    Novartis India Ltd. NOVAIN
    Nutraplus India Ltd. NUTPRO
    Omega Labora.Ltd. OMELAB
    Oriental Remedies & Herbals Ltd. ORIREM
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Procter & Gamble Health Ltd. MERCLT
    Ranbaxy Laboratories Ltd. RANLAB
    RPG Life Sciences Ltd. RPGLI
    Rubra Medicaments Ltd. RUBMED
    Sanofi India Ltd. AVEPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Trans Asia Corporation Ltd. TRAASI
    Wockhardt Ltd. WOCLTD
    Wyeth Ltd. WYELTD
    Yogi Healthcare Ltd. COREHE
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020